Yanrong Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yanrong Ye has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Fengling Yang
Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China
2 shared publications Jiaqi Zhang
Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China
2 shared publicationsLiting Zhou
Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China
2 shared publicationsMinze Chen
Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand
2 shared publicationsPan Lai
Peking University First Hospital, Beijing, China
2 shared publicationsShan Ding
Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China
2 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1810143
Integrative transcriptomic analysis revealed the roles and prognostic value of ion channels in hypertrophic cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiovascular conditions, which may be linked to ion channel dysfunction. In decades, Genetic studies in HCM patients have shown that multiple gene mutations in potassium and calcium ion channels, which may contribute to HCM progression. The direct relationship between HCM and ion channels still needs to be clarified. Method: We compared the transcriptomic differences between patients with HCM and control populations across three different datasets, and further screened through clustering and enrichment analysis, to identify hub differential expressed ion channels (DEICs) in HCM progression. By constructing pathological features of myocardial hypertrophy, fibrosis, and fibroblast activation, we sought to explore the associations between hub DEICs levels and these pathological features. Subsequently, we used single-cell RNA sequencing (scRNAseq) to clarify the expression characteristics of hub DEICs in different cells and spatial transcriptomic analysis to determine the transcriptomic features of the regions. Based on these hub DEICs, we constructed a prognostic model to evaluate its diagnostic value. Furthermore, we conducted immunoinfiltration analysis to explore their relationship with cardiac inflammatory responses. Finally, we verified these four hub genes expression alteration in transverse aortic constriction (TAC) mice. Result: Based on three transcriptome sequence datasets, we found 17 ion channels have same expression change in at least two datasets. Trough clustering and enrichment analysis, we narrowed down to four hub DEICs in all datasets, KCNC4, KCNN3, ANO1, CACNA2D3. Additionally, we found that the expression levels of these four genes were significantly associated with myocardial hypertrophy, fibrosis, and fibroblast activation. Further, through scRNAseq, we found that these four genes are primarily expressed in cardiomyocytes. Subsequently, using spatial transcriptomic sequencing, we observed that the regions where these genes were detected exhibited distinct fibrotic characteristics. Based on these hub DEICs, we constructed an expression model and found that their expression levels hold significant diagnostic value for HCM. Additionally, through immunoinfiltration analysis, we identified a correlation between the expression levels of hub DEICs and changes in macrophage proportions. We also found that the changes in gene expression observed in the TAC model were consistent with the aforementioned results. Conclusion: In this study, through integrative transcriptomic sequencing, we identified four ion channels significantly associated with the development of HCM. Furthermore, in our mechanistic exploration, we found that these associations may be linked to core pathological changes such as myocardial hypertrophy, fibrosis and changes in macrophage proportions.
- 4 May 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1810143
Open AccessIntegrative transcriptomic analysis revealed the roles and prognostic value of ion channels in hypertrophic cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiovascular conditions, which may be linked to ion channel dysfunction. In decades, Genetic studies in HCM patients have shown that multiple gene mutations in potassium and calcium ion channels, which may contribute to HCM progression. The direct relationship between HCM and ion channels still needs to be clarified. Method: We compared the transcriptomic differences between patients with HCM and control populations across three different datasets, and further screened through clustering and enrichment analysis, to identify hub differential expressed ion channels (DEICs) in HCM progression. By constructing pathological features of myocardial hypertrophy, fibrosis, and fibroblast activation, we sought to explore the associations between hub DEICs levels and these pathological features. Subsequently, we used single-cell RNA sequencing (scRNAseq) to clarify the expression characteristics of hub DEICs in different cells and spatial transcriptomic analysis to determine the transcriptomic features of the regions. Based on these hub DEICs, we constructed a prognostic model to evaluate its diagnostic value. Furthermore, we conducted immunoinfiltration analysis to explore their relationship with cardiac inflammatory responses. Finally, we verified these four hub genes expression alteration in transverse aortic constriction (TAC) mice. Result: Based on three transcriptome sequence datasets, we found 17 ion channels have same expression change in at least two datasets. Trough clustering and enrichment analysis, we narrowed down to four hub DEICs in all datasets, KCNC4, KCNN3, ANO1, CACNA2D3. Additionally, we found that the expression levels of these four genes were significantly associated with myocardial hypertrophy, fibrosis, and fibroblast activation. Further, through scRNAseq, we found that these four genes are primarily expressed in cardiomyocytes. Subsequently, using spatial transcriptomic sequencing, we observed that the regions where these genes were detected exhibited distinct fibrotic characteristics. Based on these hub DEICs, we constructed an expression model and found that their expression levels hold significant diagnostic value for HCM. Additionally, through immunoinfiltration analysis, we identified a correlation between the expression levels of hub DEICs and changes in macrophage proportions. We also found that the changes in gene expression observed in the TAC model were consistent with the aforementioned results. Conclusion: In this study, through integrative transcriptomic sequencing, we identified four ion channels significantly associated with the development of HCM. Furthermore, in our mechanistic exploration, we found that these associations may be linked to core pathological changes such as myocardial hypertrophy, fibrosis and changes in macrophage proportions.
- Open Access
- 27 February 2025
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1
Correction: Association between statin usage and mortality outcomes in aging U.S. cancer survivors: a nationwide cohort study
- 27 February 2025
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1
Open AccessCorrection: Association between statin usage and mortality outcomes in aging U.S. cancer survivors: a nationwide cohort study
- Open Access
- 5 October 2024
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 36 (1) , 1-9
Association between statin usage and mortality outcomes in aging U.S. cancer survivors: a nationwide cohort study
Background: The population of Aging cancer survivors in the United States has surged to over 16.9 million. Research on the relationship between statin usage and post-cancer survival rates remains limited. Aims: This study aims to investigate the association between statin use and various causes of mortality among aging cancer survivors. Methods: We analyzed NHANES data from 1999 to 2018, Statin usage, both hydrophilic and lipophilic, was derived from NHANES prescription records. We utilized Cox proportional hazards models to associate statin utilization with mortality, differentiating causes of death according to statin type and patterns of use. Results: Within a cohort of 2,968 participants, statin usage was categorized into non-users (1,738), hydrophilic statin users (216), and lipophilic statin users (982). Compared to those who did not use statins, individuals prescribed hydrophilic statins did not show a reduced risk of all-cause mortality (adjusted hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.72–1.41; P = 0.960), as outlined in Model 3. In contrast, the group receiving lipophilic statins exhibited a notable decrease in all-cause mortality risk (adjusted HR, 0.77; P = 0.003). Nonetheless, both hydrophilic and lipophilic statins were effective in diminishing the risk associated with cancer from its onset until death, with hydrophilic statins showing a greater level of efficacy. Discussion: The potential of statins to reduce cancer-related mortality may provide avenues for targeted clinical interventions and management strategies. Conclusions: Our study reveals that the use of lipophilic statins is significantly associated with lower all-cause and cancer-cause mortality risks among aging cancer survivors.
- 5 October 2024
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 36 (1) , 1-9
Open AccessAssociation between statin usage and mortality outcomes in aging U.S. cancer survivors: a nationwide cohort study
Background: The population of Aging cancer survivors in the United States has surged to over 16.9 million. Research on the relationship between statin usage and post-cancer survival rates remains limited. Aims: This study aims to investigate the association between statin use and various causes of mortality among aging cancer survivors. Methods: We analyzed NHANES data from 1999 to 2018, Statin usage, both hydrophilic and lipophilic, was derived from NHANES prescription records. We utilized Cox proportional hazards models to associate statin utilization with mortality, differentiating causes of death according to statin type and patterns of use. Results: Within a cohort of 2,968 participants, statin usage was categorized into non-users (1,738), hydrophilic statin users (216), and lipophilic statin users (982). Compared to those who did not use statins, individuals prescribed hydrophilic statins did not show a reduced risk of all-cause mortality (adjusted hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.72–1.41; P = 0.960), as outlined in Model 3. In contrast, the group receiving lipophilic statins exhibited a notable decrease in all-cause mortality risk (adjusted HR, 0.77; P = 0.003). Nonetheless, both hydrophilic and lipophilic statins were effective in diminishing the risk associated with cancer from its onset until death, with hydrophilic statins showing a greater level of efficacy. Discussion: The potential of statins to reduce cancer-related mortality may provide avenues for targeted clinical interventions and management strategies. Conclusions: Our study reveals that the use of lipophilic statins is significantly associated with lower all-cause and cancer-cause mortality risks among aging cancer survivors.
- Open Access
Low-dose IL-2 treatment confers anti-inflammatory effect against subarachnoid hemorrhage in mice
- Open Access
- 3 June 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (6) , e05805
Is there association of olanzapine and pulmonary embolism: A case report
Olanzapine is a second‐generation antipsychotic drug that is often used to treat schizophrenia and manic attacks. An increasing number of cases in recent years have shown that olanzapine is associated with vascular thromboembolic disease (VTD). Here, we reported a case of patient with history of taking aripiprazole, benzhexol, olanzapine, and sertraline for 5 years. He was admitted because of aggravated chest tightness, chest pain, and shortness of breath sustaining for 3 days. Laboratory examination and computed tomography angiography of the chest revealed new pulmonary embolus which involved the main trunk of the pulmonary artery and bilateral pulmonary arteries, with pneumonic infiltration in the left upper lobe. After thrombolytic therapy, the patient was out of danger.
- 3 June 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (6) , e05805
Open AccessIs there association of olanzapine and pulmonary embolism: A case report
Olanzapine is a second‐generation antipsychotic drug that is often used to treat schizophrenia and manic attacks. An increasing number of cases in recent years have shown that olanzapine is associated with vascular thromboembolic disease (VTD). Here, we reported a case of patient with history of taking aripiprazole, benzhexol, olanzapine, and sertraline for 5 years. He was admitted because of aggravated chest tightness, chest pain, and shortness of breath sustaining for 3 days. Laboratory examination and computed tomography angiography of the chest revealed new pulmonary embolus which involved the main trunk of the pulmonary artery and bilateral pulmonary arteries, with pneumonic infiltration in the left upper lobe. After thrombolytic therapy, the patient was out of danger.
- 25 March 2022
- Published by Elsevier in Thrombosis Research
- Vol. 213, 145-153
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?
- 25 March 2022
- Published by Elsevier in Thrombosis Research
- Vol. 213, 145-153
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?